| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12185-016-2071-6 |
| P698 | PubMed publication ID | 27460678 |
| P2093 | author name string | Jun Ishikawa | |
| Hiroaki Masaie | |||
| Hitoshi Yoshida | |||
| Akihisa Hino | |||
| Midori Koike | |||
| Ryota Minami | |||
| Yuma Tada | |||
| P2860 | cites work | PDGF and the progression of renal disease. | Q38185014 |
| Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia | Q38659655 | ||
| Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. | Q39835817 | ||
| Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia | Q40078173 | ||
| Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. | Q40458599 | ||
| Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney | Q40542529 | ||
| Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial | Q40807968 | ||
| Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics | Q41513106 | ||
| Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury | Q42047722 | ||
| Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). | Q46480414 | ||
| Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients | Q51604310 | ||
| Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis | Q54446241 | ||
| European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia | Q26749324 | ||
| TWEAK and the progression of renal disease: clinical translation | Q26996775 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. | Q30891587 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study | Q33363691 | ||
| Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). | Q33398716 | ||
| Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors | Q33918083 | ||
| Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat | Q33997420 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins | Q34714353 | ||
| Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors | Q35902738 | ||
| Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study | Q37025987 | ||
| A new look at platelet-derived growth factor in renal disease | Q37031269 | ||
| GFR estimation in Japan and China: what accounts for the difference? | Q37204687 | ||
| P433 | issue | 5 | |
| P921 | main subject | imatinib | Q177094 |
| P304 | page(s) | 605-611 | |
| P577 | publication date | 2016-07-26 | |
| P1433 | published in | International Journal of Hematology | Q6051416 |
| P1476 | title | Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia | |
| P478 | volume | 104 |
Search more.